Women lose up to 20% of bone density in the 5–7 years surrounding menopause. This guide covers the evidence for exercise, nutrition, supplements, and medications — with specific DEXA targets that correlate with fracture prevention.
Bone health doesn't get the attention it deserves in longevity conversations. But the data is unambiguous: osteoporotic fractures — particularly hip fractures — are among the most dangerous events in older adults. A hip fracture at age 70 carries a 20% mortality rate within one year, and among survivors, fewer than half regain their prior level of function.1
Bone isn't just structural scaffolding. It's a metabolically active organ that produces osteocalcin (a hormone that affects insulin sensitivity, testosterone production, and brain function), stores minerals, houses bone marrow (immune cell production), and communicates with muscle tissue through mechanical signaling. When bone density declines, the consequences extend far beyond fracture risk.
Women reach peak bone mass around age 30. From 30–45, bone density is relatively stable with modest losses of about 0.3–0.5% per year. Then the menopausal transition hits, and the rate accelerates dramatically:
| Phase | Annual Bone Loss Rate | Cumulative Impact |
|---|---|---|
| Premenopause (30–45) | 0.3–0.5%/year | ~5–7% total over 15 years |
| Perimenopausal transition | 2–3%/year | 10–15% over 5–7 years |
| Early postmenopause (first 5 years) | 1–2%/year | 5–10% additional |
| Late postmenopause | 0.5–1%/year | Ongoing slow loss |
The total cumulative loss can reach 20–30% of peak bone mass by age 70 without intervention. This is why baseline DEXA screening at 45–50 is so valuable — it catches the trajectory before significant loss has occurred.
Not all exercise builds bone. Bones respond to mechanical loading through a process called mechanotransduction — osteocytes (bone cells) detect strain and signal osteoblasts to build new bone. The loading must exceed the minimum effective strain (MES) threshold, which is why walking alone — while valuable for other health metrics — is insufficient for maintaining bone density.2
The LIFTMOR trial demonstrated that postmenopausal women performing heavy, compound resistance training (deadlifts, squats, overhead press) at 80–85% of 1-rep max showed significant improvements in bone density at the lumbar spine and femoral neck — the two sites most vulnerable to osteoporotic fracture.3
Protocol: 3–4 sessions per week, 3–5 sets of 5 reps at 80–85% 1RM. Prioritize: back squat or goblet squat, deadlift or hex bar deadlift, overhead press, bent-over row, hip thrust. Progressive overload is essential — the load must increase over time to continue stimulating bone adaptation.
Bones also respond to rapid, high-magnitude impact forces. Jumping, hopping, and bounding create ground reaction forces of 3–5x body weight — well above the MES threshold.
Protocol: 50–100 impacts per session, 3 times per week. Examples: box jumps (start low), jump squats, bounding, single-leg hops, skipping. Even jumping in place (10 jumps, 3 times daily) has shown measurable bone density benefits in postmenopausal women.4
Preventing falls is as important as strengthening bones. Tai chi, single-leg balance work, proprioceptive training, and reactive balance exercises reduce fall risk by 30–50% in older adults.
Swimming, cycling, yoga (most forms), light weights with high reps, and elliptical training do not generate sufficient mechanical loading to maintain or build bone density. These are valuable for cardiovascular health and mobility — but they are not bone-building activities. Don't count them as your bone density strategy.
| Nutrient | Daily Target | Evidence | Best Sources |
|---|---|---|---|
| Calcium | 1,200 mg/day | Strong | Dairy, sardines, fortified foods, leafy greens. Supplement gap with calcium citrate (better absorbed in lower-acid conditions common with aging). |
| Vitamin D3 | 2,000–5,000 IU/day | Strong | Dose to target: aim for 40–60 ng/mL serum level. Essential for calcium absorption. Virtually impossible to get enough from food alone. |
| Protein | 1.2–1.6 g/kg/day | Strong | Bone is 30% protein (collagen matrix). Inadequate protein accelerates bone loss. Distribute across 3–4 meals with 30g+ per meal. |
| Vitamin K2 (MK-7) | 100–200 μg/day | Moderate | Directs calcium to bones rather than arteries. Natto is the richest food source; supplementation is practical. Take with vitamin D. |
| Magnesium | 320–400 mg/day | Moderate-Strong | Required for vitamin D activation and bone mineralization. ~50% of women are deficient. Glycinate or citrate forms preferred. |
| Collagen peptides | 10–15 g/day | Emerging | Provides hydroxyproline and proline for the collagen matrix of bone. Several RCTs show modest benefit for bone density and joint health. |
| Boron | 3–6 mg/day | Moderate | Trace mineral that enhances calcium and magnesium retention. Found in prunes, raisins, almonds, avocados. |
Some studies have raised concerns about high-dose calcium supplementation and cardiovascular risk. The current evidence suggests: food-source calcium is preferred over supplements when possible. If supplementing, use calcium citrate in divided doses (500–600 mg max per dose) taken with meals, always paired with vitamin D and K2. Total calcium from all sources should target 1,200 mg/day — not more.
| Intervention | Mechanism | Evidence | Considerations |
|---|---|---|---|
| HRT (estrogen) | Reduces bone resorption + stimulates formation | Strong | Only therapy that both stops loss and builds new bone. Most effective when started during perimenopause/early postmenopause. Benefits reverse when discontinued. |
| Bisphosphonates (alendronate, risedronate) | Inhibits osteoclast activity (reduces resorption) | Strong | First-line for diagnosed osteoporosis. Reduces fracture risk 40–50%. Drug holidays recommended after 5 years. Rare risk of atypical fractures with long-term use. |
| Denosumab (Prolia) | RANKL inhibitor (blocks osteoclast formation) | Strong | Injection every 6 months. Effective for severe osteoporosis. Important: rapid bone loss occurs if discontinued — never stop without a transition plan. |
| Romosozumab (Evenity) | Sclerostin inhibitor (stimulates formation + reduces resorption) | Strong | Most potent bone-building drug available. 12-month course, then transition to antiresorptive. For severe osteoporosis or fracture history. |
| Raloxifene | Selective estrogen receptor modulator | Moderate | Reduces vertebral fracture risk; no benefit for hip fracture. Alternative when HRT is contraindicated. May worsen hot flashes. |
DEXA (Dual-energy X-ray Absorptiometry) measures bone mineral density at the lumbar spine, femoral neck, and total hip. Results are expressed as T-scores (standard deviations from peak young adult bone density):
| T-Score | Classification | Action Level |
|---|---|---|
| > -1.0 | Normal | Prevention: exercise, nutrition, vitamin D. Retest in 2–5 years. |
| -1.0 to -2.5 | Osteopenia | Aggressive prevention: heavy resistance training, full nutrition protocol, consider HRT. Retest annually. |
| < -2.5 | Osteoporosis | Pharmacological treatment indicated. Full exercise + nutrition protocol. Retest every 1–2 years. |
| < -2.5 + fracture history | Severe osteoporosis | Aggressive pharmacological treatment. Consider romosozumab or denosumab. Fall prevention priority. |
For women focused on long-term healthspan, aim to maintain a T-score above -1.0 at all measured sites. If your T-score declines more than 3–5% between scans, that's a signal to escalate intervention — even if you're still technically in the "normal" range. The trend matters more than the absolute number.
Bone health connects to cellular senescence, stem cell exhaustion, and altered intercellular communication. Explore the interactive map.
Hallmarks Explorer →